Abstract: A terminal control method includes: obtaining multiple terminal functions supported by a target driver module in a terminal; determining, in response to detection of an operational command indicating at least two terminal functions, a priority relationship of the at least two terminal functions; and executing, based on the priority relationship, one terminal function out of the at least two terminal functions through the target driver module.

Abstract: A ligand-drug conjugate and the use of the ligand-drug conjugate.

Abstract: A conjugate compounds or pharmaceutically acceptable salt thereof, comprises a payload and two or more kinds of cell-interacting molecules. The cell-interacting molecules are ligands capable of specifically binding to a cell surface receptor. A method of treating diseases, comprises delivering a payload to a subject.

Abstract: A display device includes: a display screen including a display screen body and a display screen edge part, at least one edge of the display screen being bent toward a back side of the display screen to form the display screen body and the display screen edge part; a first light sensor arranged on a back side of the display screen body and configured to detect a brightness of ambient light of a front side of the display screen body; a light source arranged on a front side of the display screen edge part and configured to emit light according to a preset brightness; and a second light sensor arranged on a back side of the display screen edge part and configured to detect a brightness of the light source.

Abstract: The present disclosure provides an in vitro proliferation medium, an in vitro culture kit and an in vitro proliferation culture method of umbilical cord blood (UCB)-derived natural killer (NK) cells, and relates to the technical field of cell in vitro culture. In the present disclosure, the in vitro proliferation medium does not include animal serum to reduce immune responses when being used, with better safety. The in vitro proliferation medium is used to proliferate the UCB-derived NK cells in vitro, with simple and easy operations and low cost, and without coating, sorting and trophoblast cells. The medium does not include animal-derived ingredients, and has desirable safety and stability. The medium can be used for direct culture of peripheral blood mononuclear cells (PBMCs) isolated by Ficoll, and harvest more NK cells that meet clinical use standards.

Abstract: A conjugate compounds or pharmaceutically acceptable salt thereof, comprises a payload and two or more kinds of cell-interacting molecules. The cell-interacting molecules are ligands capable of specifically binding to a cell surface receptor. A method of treating diseases, comprises delivering a payload to a subject.

Abstract: The present disclosure discloses a conjugate compound or a pharmaceutically acceptable salt thereof, comprising a payload and two targeting molecules. Further disclosed herein is a pharmaceutical composition, comprising the conjugate compound or the pharmaceutically acceptable salt thereof. The present disclosure additionally relates to a method for delivering a payload to a subject in need thereof, and a method for treating a disease, wherein the methods comprise administering to the subject a therapeutically effective amount of the conjugate compound or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition as disclosed herein.

Abstract: A transformer core for a dry-type transformer includes a laminated construction having several groups of stacked laminations that form a step-lap sequence of laminations. Each group in the step-lap sequence has a mean length different than an adjacent group in the step-lap sequence and has at least two identical laminations per group, wherein at least one group has at least four identical laminations. Methods of assembling a transformer core are also provided, as are other aspects.

Abstract: A transformer core for a dry-type transformer includes a laminated construction having several groups of stacked laminations that form a step-lap sequence of laminations. Each group in the step-lap sequence has a mean length different than an adjacent group in the step-lap sequence and has at least two identical laminations per group, wherein at least one group has at least four identical laminations. Methods of assembling a transformer core are also provided, as are other aspects.

Abstract: A conjugate compounds or pharmaceutically acceptable salt thereof, comprises a payload and two or more kinds of cell-interacting molecules. The cell-interacting molecules are ligands capable of specifically binding to a cell surface receptor. A method of treating diseases, comprises delivering a payload to a subject.